A Kotronen, T Seppänen-Laakso, J Westerbacka, … - Diabetes, 2009 - Am Diabetes Assoc RESULTS—The absolute (nmol/mg) hepatic concentrations of diacylglycerols but
not ceramides were increased in the NAFL + group compared with the NAFL −
group. The livers of the NAFL + group contained proportionally less ... Cited by 4 - Related articles - All 3 versions
A Peter, A Cegan, S Wagner, R Lehmann, N … - Clinical Chemistry, 2009 - Am Assoc Clin Chem BACKGROUND: Stearoyl-coenzyme A desaturase 1 (SCD1) catalyzes the limiting step
of monounsaturated fatty acid synthesis in humans and is an important player in
triglyceride generation. SCD1 has been repeatedly im- plicated in the ... Cited by 1 - Related articles - All 2 versions
- ►ahajournals.org [PDF] F Karpe, L Hodson - Arteriosclerosis, Thrombosis, and Vascular Biology, 2008 - Am Heart Assoc Accordingly, assessment of the surrogate marker for SCD1 activity in whole
plasma may generate data that are very difficult to interpret when groups with
different triglyceride concentrations are compared, and, in fact, ... Cited by 2 - Related articles - All 3 versions
N Stefan, A Peter, A Cegan, H Staiger, J … - Diabetologia, 2008 - Springer Abstract Aims/hypothesis Stearoyl-CoA desaturase 1 (SCD1) is the rate-limiting
enzyme in monounsaturated fatty acid synthesis. It is imperative for the
assembly of VLDL particles, which transport triacylglycerol (TG) from liver ... Cited by 6 - Related articles - BL Direct - All 3 versions
P Mathurin, A Hollebecque, L Arnalsteen, D … - Gastroenterology, 2009 - Elsevier Five years after surgery, levels of fibrosis increased significantly, but 95.7%
of patients maintained a fibrosis score ≤ F1. The percentage of patients with
steatosis decreased from 37.4% before surgery to 16%, the NAFLD score from ... Cited by 1 - Related articles - All 34 versions
- ►vghtpe.gov.tw [PDF] SM Chen, CY Liu, SR Li, HT Huang, CY Tsai, … - Journal of the Chinese Medical Association, 2008 - Elsevier A prospective, case-controlled study was conducted. A total of 54 subjects with
NAFLD were subdivided into 3 groups: (1) diet plus exercise group (DPE group, n
= 16); (2) exercise group (E group, n = 23); and (3) control group (C ... Cited by 1 - Related articles - All 4 versions
A Gastaldelli, SA Harrison, R Belfort, J … - Hepatology, 2009 - interscience.wiley.com Pioglitazone treatment improves insulin resistance, glucose metabolism, hepatic
steatosis and necro-inflammation in patients with IGT/T2DM and non-alcoholic
steatohepatitis (NASH). Because abnormal lipid metabolism/elevated plasma ... Cited by 1 - Related articles - All 2 versions
RP Witek, WC Stone, FG Karaca, WK Syn, TA … - Hepatology, 2009 - interscience.wiley.com Nonalcoholic Fatty Liver Disease is a potentially progressive liver disease that
culminates in cirrhosis. Cirrhosis occurs more often in individuals with
nonalcoholic steatohepatitis (NASH) than in those with steatosis (NAFL). ... Cited by 1 - Related articles - All 2 versions
K Kantartzis, A Peter, F Machicao, J Machann, … - Diabetes, 2009 - ncbi.nlm.nih.gov Objective- In a genome-wide association scan the rs738409 C>G single nucleotide
polymorphism (SNP) in the patatin-like phospholipase-3-gene (PNPLA3) was
strongly associated with increased liver fat, but not with insulin ... Cited by 1 - Related articles - All 3 versions
NA Johnson, T Sachinwalla, DW Walton, K … - Accepted Article Online: Jun, 2009 - interscience.wiley.com Weight loss remains the most common therapy advocated for reducing hepatic lipid
in obesity and non-alcoholic fatty liver disease. Yet, reduction of body weight
by lifestyle intervention is often modest and thus, therapies which ... Cited by 1 - Related articles - All 2 versions
